ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage ...
Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival. When imatinib (Gleevec; Novartis), the first-ever tyrosine kinase inhibitor, made its ...
Data Trends provide quick, visually memorable data-driven information and insights that are useful in clinical practice. Here, we explore recent treatment updates in chronic lymphocytic leukemia (CLL) ...
Imatinib marked a paradigm shift in CML treatment, offering significant improvements over previous therapies and reducing adverse effects. Despite imatinib's success, resistance and the need for ...
Chronic myeloid leukemia (CML) is an oncogenic hematologic disorder defined by the BCR-ABL1 fusion gene, which initiates pathological proliferation of myeloid lineage cells. While tyrosine kinase ...
Myeloproliferative neoplasms (MPN) are clonal disorders originating from hematopoietic stem cells with altered tyrosine kinase signaling, resulting in the proliferation of one or more myeloid lineages ...
We recently published 10 Market Stars Behind Millionaire-Making in 2025. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the top performers. Terns Pharmaceuticals climbed by 629.64 percent in 2025 ...
With the combination of asciminib plus a TKI, 91% of CML patients had attained a major molecular response by month 36. Combining asciminib, a first-in-class BCL::ABL1 inhibitor, with a tyrosine kinase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results